高级检索
    涂海燕. AZD9291和Rociletinib在EGFR抑制剂耐药的非小细胞肺癌中的安全性和有效性[J]. 循证医学, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
    引用本文: 涂海燕. AZD9291和Rociletinib在EGFR抑制剂耐药的非小细胞肺癌中的安全性和有效性[J]. 循证医学, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
    shu
    TU Hai-yan. Safety and Activity, AZD9291 and Rociletinib in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
    Citation: TU Hai-yan. Safety and Activity, AZD9291 and Rociletinib in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
    shu

    AZD9291和Rociletinib在EGFR抑制剂耐药的非小细胞肺癌中的安全性和有效性

    Safety and Activity, AZD9291 and Rociletinib in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回